WEBULL
WebtradeDownload

Is Long Term Blood Pressure Data Altering The Investment Case For Mineralys Therapeutics (MLYS)?

Simply Wall St · 2d ago
  • Mineralys Therapeutics reported long term Transform HTN extension data showing a 17.8 mmHg absolute reduction in systolic blood pressure at 48 weeks and 56% of participants below 130 mmHg, with lorundrostat generally well tolerated and no new major safety signals.
  • The trial kept more than 90% of 632 eligible participants on lorundrostat through 48 weeks. This persistence speaks directly to real world style use for a chronic hypertension therapy where adherence is often poor.
  • The next area of focus will be how Mineralys Therapeutics' pre revenue investment narrative aligns with these sustained 48 week lorundrostat blood pressure results.
Capitalize on the hypertension theme by scanning 36 healthcare AI stocks that could also be working on tech-enabled approaches to treatment adherence and chronic care.

Mineralys Therapeutics Investment Narrative Recap

To own Mineralys Therapeutics, you need confidence that lorundrostat can move from clinical asset to an approved hypertension backbone and support a full commercial buildout. The long term Transform HTN data line up with that belief, but the most important near term inflection remains the FDA review with the December 22, 2026 PDUFA date.

The analyst consensus Narrative on Simply Wall St frames the main risk as timing and outcome of that approval process, compounded by ongoing operating losses and competitive aldosterone synthase programs. The new efficacy and tolerability readout helps the scientific story. It does not remove regulatory uncertainty or the funding demands of a pre revenue launch plan.

The single announcement most tightly tied to this trial update is the Transform HTN and Launch HTN disclosure that lorundrostat cut automated office systolic blood pressure by 17.8 mmHg through 48 weeks, with 56% of patients below 130 mmHg and 92% completing follow up. That durability signal speaks directly to how Mineralys Therapeutics is positioning the drug in real world style chronic use.

For catalysts, this matters because regulators and future prescribers often look for sustained control, not just short term reductions. Safety details such as 4.3% serious adverse events, 5.9% discontinuations, and 5.1% hyperkalemia requiring dose changes will also shape how doctors and potential partners weigh the benefit risk trade off against competing agents once any approval decision arrives.

Mineralys Therapeutics' analyst narrative points to forecast revenue of US$463.2 million and earnings of US$15.2 million by 2029, from no revenue and a current loss of US$349.6 million. This implies earnings would need to improve by about US$364.8 million over that period to reach the consensus profit estimate.

Uncover why Mineralys Therapeutics' fair value indicates a 191% potential upside to its current price that may not last much longer.

NasdaqGS:MLYS 1-Year Stock Price Chart
NasdaqGS:MLYS 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate view puts Mineralys Therapeutics’ commercial execution as the real swing factor rather than just FDA timing. The most optimistic analysts were already penciling in about US$535.6 million of 2029 revenue and roughly US$98.0 million of earnings before this Transform HTN update, which could shift their story again. You should compare that upbeat script with more cautious forecasts and decide which assumptions feel realistic.

Explore 2 other Mineralys Therapeutics fair value estimates, including one that suggests as much as 531% upside from the current price!

The Verdict Is Yours

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking for more investment ideas beyond Mineralys Therapeutics?

Once you have a handle on Mineralys Therapeutics, it can help to set it alongside a few different types of opportunities so you can decide where it fits in your wider portfolio.